LTC Webinar: The relationship between the VC and its portfolio companies
2 July 2020
‘The reason we are so excited about Biotech investments is that the exits we have are oversized in terms of returns. But also with that - we are making an impact on the way we live our lives.’
We were pleased to host a webinar with ARTIS Ventures, pioneering investors in techbio: at the intersection of life sciences and computer sciences. The discussion focused on the relationship between the VC and its portfolio companies. It was great to see first-hand the close relationships between Artis and the CEOs/ Founders within their portfolio.
A special thank you to our fantastic speakers:
-
Vas Bailey, PhD, partner at ARTIS Ventures which invests in breakthrough healthcare companies.
-
Connor Landgraf, co-founder and CEO of Eko, on a mission to improve monitoring for cardiovascular and pulmonary disease patients.
-
Pavle Jeremić, CEO and founder of Aether Biomachines, a company operating at the intersection of manufacturing, synthetic biology, and deep learning.
-
Daniel Dornbusch, CEO at Excision BioTherapeutics, developing advanced gene editing therapeutics to treat life-threatening diseases caused by viral infections.
It is always encouraging to hear about breakthroughs and success stories in BioTech and healthcare! The future feels more positive as a result of some of the great work discussed.
Please also subscribe to our newsletter to receive information about our future activities.